Literature DB >> 35605261

Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies.

Li Song1,2, Zhangyi Ouyang1,3, David Cohen1, Yang Cao1,4, Jennifer Altreuter1, Gali Bai1, Xihao Hu1, Kenneth J Livak5,6, Heng Li1,7, Ming Tang1, Bo Li8, X Shirley Liu1,2,9.   

Abstract

We applied our computational algorithm TRUST4 to assemble immune receptor (T-cell receptor/B-cell receptor) repertoires from approximately 12,000 RNA sequencing samples from The Cancer Genome Atlas and seven immunotherapy studies. From over 35 million assembled complete complementary-determining region 3 sequences, we observed that the expression of CCL5 and MZB1 is the most positively correlated genes with T-cell clonal expansion and B-cell clonal expansion, respectively. We analyzed amino acid evolution during B-cell receptor somatic hypermutation and identified tyrosine as the preferred residue. We found that IgG1+IgG3 antibodies together with FcRn were associated with complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity or phagocytosis. In addition to B-cell infiltration, we discovered that B-cell clonal expansion and IgG1+IgG3 antibodies are also correlated with better patient outcomes. Finally, we created a website, VisualizIRR, for users to interactively explore and visualize the immune repertoires in this study. See related Spotlight by Liu and Han, p. 786. ©2022 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35605261      PMCID: PMC9299271          DOI: 10.1158/2326-6066.CIR-21-0965

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   12.020


  64 in total

1.  Amino acid substitution matrices from protein blocks.

Authors:  S Henikoff; J G Henikoff
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma.

Authors:  Kristi Elkins; Bing Zheng; Maryann Go; Dionysos Slaga; Changchun Du; Suzie J Scales; Shang-Fan Yu; Jacqueline McBride; Ruth de Tute; Andy Rawstron; Andrew S Jack; Allen Ebens; Andrew G Polson
Journal:  Mol Cancer Ther       Date:  2012-07-17       Impact factor: 6.261

3.  Protein structure modeling with MODELLER.

Authors:  Benjamin Webb; Andrej Sali
Journal:  Methods Mol Biol       Date:  2014

4.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.

Authors:  Seung Tae Kim; Razvan Cristescu; Adam J Bass; Kyoung-Mee Kim; Justin I Odegaard; Kyung Kim; Xiao Qiao Liu; Xinwei Sher; Hun Jung; Mijin Lee; Sujin Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Hyuk Lee; Mingew Choi; AmirAli Talasaz; Peter Soonmo Kang; Jonathan Cheng; Andrey Loboda; Jeeyun Lee; Won Ki Kang
Journal:  Nat Med       Date:  2018-07-16       Impact factor: 53.440

5.  Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells.

Authors:  Huifang Li; Francisco Borrego; Satoshi Nagata; Mate Tolnay
Journal:  J Immunol       Date:  2016-04-13       Impact factor: 5.422

6.  CCMpred--fast and precise prediction of protein residue-residue contacts from correlated mutations.

Authors:  Stefan Seemayer; Markus Gruber; Johannes Söding
Journal:  Bioinformatics       Date:  2014-07-26       Impact factor: 6.937

7.  TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors:  Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal:  Nature       Date:  2018-02-14       Impact factor: 49.962

Review 8.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561

9.  Human HMGA2 protein overexpressed in mice induces precursor T-cell lymphoblastic leukemia.

Authors:  A Efanov; N Zanesi; V Coppola; G Nuovo; B Bolon; D Wernicle-Jameson; A Lagana; A Hansjuerg; F Pichiorri; C M Croce
Journal:  Blood Cancer J       Date:  2014-07-11       Impact factor: 11.037

10.  B cells and tertiary lymphoid structures promote immunotherapy response.

Authors:  Beth A Helmink; Sangeetha M Reddy; Jianjun Gao; Shaojun Zhang; Rafet Basar; Rohit Thakur; Keren Yizhak; Moshe Sade-Feldman; Jorge Blando; Guangchun Han; Vancheswaran Gopalakrishnan; Yuanxin Xi; Hao Zhao; Rodabe N Amaria; Hussein A Tawbi; Alex P Cogdill; Wenbin Liu; Valerie S LeBleu; Fernanda G Kugeratski; Sapna Patel; Michael A Davies; Patrick Hwu; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Reetakshi Arora; Scott Woodman; Emily Z Keung; Pierre-Olivier Gaudreau; Alexandre Reuben; Christine N Spencer; Elizabeth M Burton; Lauren E Haydu; Alexander J Lazar; Roberta Zapassodi; Courtney W Hudgens; Deborah A Ledesma; SuFey Ong; Michael Bailey; Sarah Warren; Disha Rao; Oscar Krijgsman; Elisa A Rozeman; Daniel Peeper; Christian U Blank; Ton N Schumacher; Lisa H Butterfield; Monika A Zelazowska; Kevin M McBride; Raghu Kalluri; James Allison; Florent Petitprez; Wolf Herman Fridman; Catherine Sautès-Fridman; Nir Hacohen; Katayoun Rezvani; Padmanee Sharma; Michael T Tetzlaff; Linghua Wang; Jennifer A Wargo
Journal:  Nature       Date:  2020-01-15       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.